Color Health

What is Color Health and who sells it?

Color Health, Inc. (originally Color Genomics) is based in Burlingame, California, and led by CEO Othman Laraki. Wikipedia lists the co-founders as Elad Gil, Nish Bhat, Taylor Sittler and Laraki. The company's own timeline starts in 2015, when it launched its first clinical genetic-testing product, though some aggregators say 2013 or 2014. The About page lists the American Cancer Society partnership in 2023 and says the cancer care solution gained traction with employers in 2024. Color's homepage and About page claim more than 7 million patients served. The "over 2 million" figure does not appear on the About page.

Funding figures come from aggregators and are not audited. Tracxn lists a $15M Series A, a Series D of $167M at a $1.5B valuation, and a $100M Series E led by General Catalyst in November 2021 at a $4.6B valuation. Total raised is $491M (Tracxn) or $523M (Silicon Valley Investclub). No ownership change is listed.

The company's history, per its About page: a 2018 role as an NIH All of Us genome center with the Broad Institute, a COVID testing lab and programs in 2020, and an American Cancer Society partnership in 2023. The current homepage headline is "Care for cancer. Reinvented." The About page calls Color "the only nationwide, oncologist-led Virtual Cancer Clinic" serving employer, union, health plan and public-sector populations.

What does Color do well?

Color lists an oncologist-led care team, a licensed medical group across all 50 states and 24/7 access to oncologist-led clinical care. At-home cancer screening and testing are part of it.

Coverage runs from prevention and early detection to treatment planning, active treatment support, survivorship and return to work. The homepage says Color follows up on "100% of abnormal results", which is a vendor claim.

An Expert Medical Opinion and Peer to Peer program and an Expert Oncology Network are listed.

The About page states a "CAP-accredited and CLIA-certified laboratory" with state licenses. A Color blog post dated May 5, 2026 says the Virtual Cancer Clinic is the first virtual cancer organization to earn the ASCO Certified designation, which ASCO builds on its Oncology Medical Home Standards. Both claims come from Color and can be confirmed with the accrediting bodies.

In an OpenAI case study, Color describes a cancer copilot built on GPT-4o that extracts patient data and guidelines, builds personalized screening plans and diagnostic workup, and drafts medical-necessity documents and pre-authorizations. The same page says the "output is analyzed by a clinician at every step". FDA status is not stated for the copilot or the service. Color's blog describes an at-home HPV self-collection kit as FDA-cleared. The kit is a third party's product, and a search of the FDA 510(k) database found no clearance held by Color Health or Color Genomics. Color therefore uses a cleared kit in its screening program and does not list an FDA-cleared product of its own.

For an employer, the practical appeal is a single point of contact for staff who get an abnormal screening result, with clinicians who act on it.

Where does it fall short?

The outcome claims come with no shown method. The homepage lists "66% faster diagnosis", "77% increase in screening adherence", "more than 75% of costly care gaps closed", a "3.8:1 ROI in Year 1" and "more than 7M patients served". No methodology appears next to them. The primary document is Color's 2025 impact report, and the claims remain vendor figures until a buyer has read its methodology.

No independent outcome data or reviews are listed for the Virtual Cancer Clinic. Praise comes from Color, from press releases such as a January 2026 partnership announcement with Evry Health, and from the OpenAI case study. An employer or health plan has to rely on references from existing customers.

Compliance is documented for HIPAA only. Color's Notice of Privacy Practices (updated July 24, 2026) says Color Health, Inc., its affiliated medical groups and its laboratory handle protected health information under HIPAA, and that for some customers Color acts as a business associate under business associate agreements. Its informed-consent page describes the laboratory as a HIPAA-covered genetic testing laboratory. No public SOC 2 or HITRUST statement is published, which matters to a health plan or union fund running a security review.

Integration with the buyer's own systems is thin on paper. The OpenAI case study lists EHR integration as a goal without naming systems. A Metriport customer page says Color connects to the HIE network through Metriport's API, sends records back to that network and monitors ADT alerts. It names no EHR such as Epic or Oracle Health, so a plan or provider network that expects records to flow into its own EHR should ask how.

The service is also contract-only. Color publishes no price, so an employer cannot compare cost per covered life against other cancer-navigation programs before a sales call.

What does Color cost?

Quote only. Color publishes no price and sells by contract to organizations. The website's call to action is "Let's talk", and no billing period is stated.

How does Color compare?

No like-for-like comparison exists, and the competitor lists disagree. Tracxn names Accolade, HealthEquity, Sword Health, Hinge Health, Sharecare and 23andMe, a broad set. CB Insights puts Color in "virtual cancer care navigation" beside Exact Sciences, Freenome, Ambry Genetics, GRAIL and Invitae. A vendor-review site lists Cancer Expert Now, AccessHope, Osara Health and Mayo Complex Care.

An employer shortlisting should treat these lists as starting points, not a ranking: they mix navigation services, genetic-testing companies and general digital-health vendors. Neither prices nor outcomes are public for any of them.

What does the evidence say?

Color's scientific-publications page lists about 81 items, mostly conference posters and genomics papers from 2016 to 2025, including papers in Nature Medicine, PNAS, NEJM and JAMA Oncology. Only one item, a 2024 International Foundation of Employee Benefit Plans paper, is titled as being about the virtual cancer clinic and screening adherence. Two 2025 ISPOR posters and an ASCO poster concern virtual cancer programs. A PubMed search finds two papers that name Color in the title or abstract: a 2025 article in the American Journal of Medical Genetics Part A on consumer genetic testing for germline cancer and cardiovascular risk (PMID 40728253) and a 2026 Journal of Genetic Counseling study of how consumers used genetic counseling after a 59-gene panel (PMID 42499155). Both study Color's genetic test and neither evaluates the Virtual Cancer Clinic or the copilot. An affiliation search shows about 40 papers with Color authors.

No community reviews and no independent evaluation of the clinic's outcomes are listed. A benefits buyer has a procurement step ahead of them: ask Color for the 2025 impact report's methodology and for references from a customer of similar size.

Who is Color for?

A benefits director at a self-insured employer with several thousand covered lives who wants one cancer-care partner for screening, navigation and second opinions. A union health fund or a public-sector plan with the same need. A health plan adding a virtual oncology benefit.

It is not for a solo physician seeking an AI tool, a hospital oncology department looking for decision support inside its own EHR, or a buyer who requires published outcome data before signing.

The verdict

Color is now a cancer-care service with real accreditations and a large funding history, backed by outcome claims the public record does not yet test. If you are an organization buying cancer care, request the impact report and a reference call. If you are a clinician shopping for software, this is not the category.